Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease

Brain Research Bulletin
Luigi F AgnatiS Ferré

Abstract

Adenosine A2A receptors are a new target for drug development in Parkinson's disease. Some experimental and clinical data suggest that A2A receptor antagonists can provide symptomatic improvement by potentiating the effects of L-DOPA as well as a decrease in secondary effects such as L-DOPA-induced dyskinesia. L-DOPA-induced behavioral sensitization in unilateral 6-hydroxydopamine-lesioned rats is frequently used as an experimental model of L-DOPA-induced dyskinesia. In the present work this model was used to evaluate the effect of the A2A receptor agonist CGS 21680 and the A2A receptor antagonist MSX-3 on L-DOPA-induced behavioral sensitization and 6-hydroxydopamine-induced striatal dopamine denervation. L-DOPA-induced behavioral sensitization was determined as an increase in L-DOPA-induced abnormal involuntary movements and enhancement of apomorphine-induced turning behavior. Striatal dopamine innervation was determined by measuring tyrosine-hydroxylase immunoreactivity. Chronic administration of MSX-3 was not found to be effective at counteracting L-DOPA-induced behavioral sensitization. On the other hand, CGS 21680 completely avoided the development of L-DOPA-induced behavioral sensitization. The analysis of the striatal do...Continue Reading

References

May 1, 1986·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·L A Sternberger, N H Sternberger
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·R BordetJ C Schwartz
May 5, 1998·Neurology·Y Agid
May 2, 2001·Parkinsonism & Related Disorders·S FerréK Fuxe
Oct 23, 2002·Journal of Neuroscience Research·Takeshi KiharaAkinori Akaike
Mar 12, 2003·Bioorganic & Medicinal Chemistry·Jacobus P PetzerNeal Castagnoli
Apr 1, 2003·Nature Neuroscience·Barbara PicconiPaolo Calabresi
Apr 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Marzena Karcz-KubichaSergi Ferré
May 13, 2003·Nature Medicine·Erwan BézardPierre Sokoloff
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Oliver KudlacekStefan Boehm
Aug 13, 2003·Neurology·W Bara-JimenezT N Chase
Aug 13, 2003·Neurology·Robert A HauserUNKNOWN Istradefylline US-001 Study Group

❮ Previous
Next ❯

Citations

Apr 29, 2008·Purinergic Signalling·Marek CieślakAndrzej Wojtczak
Dec 25, 2009·Neuromolecular Medicine·Enrica BaldelliLuigi F Agnati
Sep 29, 2009·Neurochemistry International·Hélio Vitoriano NobreGlauce Socorro de Barros Viana
May 20, 2008·Pharmacology, Biochemistry, and Behavior·Gang ZhaoLi-He Guo
Jul 10, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Kjell FuxeLuigi Agnati
Sep 4, 2008·Journal of Cellular Physiology·Cynthia St HilaireKatya Ravid
Mar 2, 2005·Pharmacology & Therapeutics·Kui XuMichael Schwarzschild
Feb 22, 2011·Expert Opinion on Drug Metabolism & Toxicology·Nikoletta SzabóLászló Vécsei
Jul 2, 2016·Journal of Neurochemistry·Rodrigo A Cunha
Nov 23, 2006·São Paulo Medical Journal = Revista Paulista De Medicina·Ming Chi ShihRodrigo Affonseca Bressan
Oct 27, 2006·Journal of Neural Transmission·K FuxeL F Agnati

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here